Article Details
Retrieved on: 2025-06-04 13:26:16
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article announces a Phase 2 study by Biodexa Pharmaceuticals on Tolimidone for Type 1 Diabetes treatment. Tolimidone, originally developed by Pfizer, acts through signal transduction and Lyn kinase activation, demonstrating potential in insulin signaling amplification. Tags like 'Diabetes', 'MTOR inhibitors', and others reflect the biochemical focus and development context.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here